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Abstract In loading tests using galactosylceramide which had 
been labelled with tritium in the ceramide moiety, living skin 
fibroblast lines derived from the original prosaposin-deficient 
patients had a markedly reduced capacity to degrade galacto-
sylceramide. The hydrolysis of galactosylceramide could be 
partially restored in these cells, up to about half the normal rate, 
by adding pure saposin A, pure saposin C, or a mixture of these 
saposins to the culture medium. By contrast, saposins B and D 
had little effect on galactosylceramide hydrolysis in the 
prosaposin-deficient cells. Cells from P-galactocerebrosidase-
deficient (Krabbe) patients had a relatively high residual 
galactosylceramide degradation, which was similar to the rate 
observed for prosaposin-deficient cells in the presence of saposin 
A or C. An SV40-transformed fibroblast line from the original 
saposin C-deficient patient, where saposin A is not affected, 
showed normal degradation of galactosylceramide. The findings 
support the hypothesis, which was deduced originally from in 
vitro experiments, that saposins A and C are the in vivo 
activators of galactosylceramide degradation. Although the 
results with saposin C-deficient fibroblasts suggest that the 
presence of only saposin A allows galactosylceramide breakdown 
to proceed at a normal rate in fibroblasts, it remains to be 
determined whether saposins A and C can substitute for each 
other with respect to their effects on galactosylceramide 
metabolism in the whole organism. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The degradation of sphingolipids by lysosomal lipid hydro-
lases is facilitated by sphingolipid activator proteins, with the 
enzymatic deglycosylation of monohexosyl and small oligo-
saccharyl ceramides (for review, see [1]) and the desulfation 
of sulfogalactosyl ceramide (sulfatide [2]) being dependent on 
activator proteins. In addition, the enzymatic hydrolysis of 
ceramide to sphingosine and fatty acid is also mediated by 
an activator protein [3]. 
Two genes encoding sphingolipid activator proteins have 
been identified: the gene for prosaposin and one for the 
GM2 ganglioside activator [1]. Prosaposin is a precursor pro-
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Abbreviations: gal-cer, galactosylceramide; Prosap-d, prosaposin defi-
cient/deficiency; sap A, sap B, sap C, sap D, saposins A, B, C and D, 
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tein giving rise to four saposin (sap) activators, sap A, B, C 
and D, through proteolytic cleavage [4]. Two mechanisms of 
action appear to be involved in sphingolipid activator func-
tion. Some activators mobilize glycosphingolipids by loosen-
ing the sphingolipid's ceramide moiety within the membrane, 
thereby making the sphingolipid's glycosyl groups more acces-
sible to sphingolipid hydrolases [5]. Other activators (e.g. sap 
C) bind to a given lipid hydrolase (e.g. glucosylceramide-(5-
glucosidase = (3-glucocerebrosidase), rather than the sphingo-
lipid, and the ensuing activator/enzyme complex is more ef-
fective at hydrolyzing its sphingolipid substrate [6]. 
The investigation of activator-deficient sphingolipidoses (for 
review, see [1]) has helped to elucidate the role of sphingolipid 
activator proteins in vivo, and has revealed that some activa-
tors do not always manifest the expected effects, as predicted 
from in vitro studies, in vivo. For example, in vitro studies 
indicated that sap A [7], sap B [8], sap C [7-10] and sap D 
[7,11] can stimulate sphingomyelin hydrolysis. However, stud-
ies on the human cases of prosaposin deficiency (Prosap-d) 
[12-14], as well as the Prosap-d mouse [15], showed normal 
levels of sphingomyelin in various tissues, suggesting that sap-
osins are not required for sphingomyelin hydrolysis in vivo. 
These findings were supported by studies on Prosap-d fibro-
blasts which failed to show any defect in sphingomyelin deg-
radation per se in lipid loading studies [12] or in sphingomye-
linase assays [12,14,16]. Clearly, the function of a given 
activator should always be checked in in vivo systems to con-
firm or clarify any conclusions drawn from in vitro investiga-
tions. 
Of the four saposins, the crucial role of sap B in the sol-
ubilization of some sphingolipid substrates (e.g. sulfatide and 
globotriaosylceramide [17]) has been clearly established (for 
review, see [18]), and recently the role of sap D in the activa-
tion of ceramide hydrolysis by acid ceramidase has been rec-
ognized [3,16,19]. 
The involvement of sap C in the deglucosylation of gluco-
sylceramide by (3-glucocerebrosidase has been supported by 
the finding that a genetic deficiency of sap C (SapC-d) resulted 
in a glucosylceramide storage disease resembling a neurologic 
form of Gaucher disease [20]. Meanwhile, in vitro studies in-
dicated that sap C also activated the degalactosylation of gal-
actosylceramide (gal-cer) [21] and lactosylceramide [22]. The 
dependence on one or more saposins for the degalactosylation 
of lactosylceramide in vivo was clearly established in studies 
on the Prosap-d patients, where all four saposins are absent 
[12-14]. 
So far, sap A has only been characterized in vitro. This 
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saposin was found to have similarities to sap C, including a 
mutual specificity for glucosylceramide and gal-cer hydrolysis 
[21], but differed, to some extent, from sap C in its binding to 
a lipid hydrolase [6]. 
Whether sap C, sap A, or other activator factors, also con-
trol the degradation of gal-cer in vivo has not yet been estab-
lished. Only the enzymic factor ((3-galactocerebrosidase) in-
volved in gal-cer degradation has a proven role in gal-cer 
turnover in vivo, as evidenced by its deficiency in Krabbe 
disease. 
To study the role of sphingolipid activators in the degrada-
tion of gal-cer in vivo, we undertook loading tests in fibro-
blast lines derived from patients with deficiencies in sap A 
and/or sap C. Cells from the original SapC-d patient [20] 
and from the Prosap-d patients [12,13] were available. A 
marked reduction in the in vitro activity of (3-galactocerebro-
sidase in the Prosap-d patients [12,14,16] had already pro-
vided indirect evidence of an impairment in gal-cer catabo-
lism. 
The present study reports the results of gal-cer loading tests 
in Prosap-d, SapC-d and other cell lines. Our data provide 
evidence that sap A and sap C can activate gal-cer hydrolysis 
in vivo. The question remains open whether only one or both 
of these saposins is necessary to maintain adequate gal-cer 
turnover in the living organism. 
2. Materials and methods 
2.1. Cell lines 
Control, Prosap-d, SapC-d, P-galactocerebrosidase-deficient (early 
infantile Krabbe disease), p-galactosidase-deficient (early infantile 
GM1 gangliosidosis) and ceramidase-deficient (infantile Farber dis-
ease) cells were grown from the stocks of frozen skin fibroblasts in 
our diagnostic laboratory. Some of these cell lines were also used after 
they were SV40-transformed. Transformation did not affect the bio-
chemical characteristics of the Prosap-d cells [16], and retention of the 
sap C deficiency in transformed SapC-d cells was confirmed immuno-
logically (Christomanou, unpublished) by double immunodiffusion 
[20]. 
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2.2. Activator proteins 
The preparation of crude sap C used in these studies was a post-
DE52 column, concanavalin A-binding fraction [23] containing sap C 
and minor components of sap A, B and D. Pure saposins, sap A, B, C 
and D, were prepared from Gaucher disease spleen as described [24] 
and their purity was checked by SDS-PAGE and reverse phase HPLC 
(C4 column). Immunoblotting using monospecific antibodies 
[3,7,11,21,25] confirmed that there was no cross-contamination with 
other saposins in these preparations. 
2.3. Radioactive gal-cer lipid substrate 
The hydroxy fatty acid fraction of galactosylceramides from bovine 
brain (Sigma-Aldrich, Deisenhofen, Germany, no. C 8752) was cata-
lytically hydrogenated with tritium across the ceramide double bonds 
and re-purified using two-dimensional thin layer chromatography on 
silica gel plates. The specific radioactivity was 3000 dps/nmol. This 
substrate was used for the lipid loading tests (see below) and for the 
determination of P-galactocerebrosidase activity in vitro [26]. 
2.4. Cell culturing 
Before further use, the fibroblasts were maintained for 1 week in 
standard medium 199 (C.C. Pro GmbH, D-67433 Neustadt, Ger-
many) with glutamine and 10% (v/v) fetal calf serum under an atmos-
phere of 5% C0 2 . 
2.5. Lipid loading tests with gal-cer 
Layers of freshly confluent fibroblasts in 25 cm2 flasks (about 0.4 
mg protein) were incubated with 5 ml standard medium to which 13 
nmol radioactive gal-cer, solubilized in 75 |xl ethanol, was added. In 
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Fig. 1. Thin layer chromatographic analysis of recovered radioactive 
cellular lipids after loading intact fibroblast cultures with galactosyl 
[3H]ceramide (gal-cer) for 3 days. The ordinate indicates the relative 
amount of radioactivity, where cts is counts per 13 min, and the ab-
scissa indicates the distance moved in cm on the thin layer plates. 
The origin was at 1 cm and the solvent front at 18 cm. Please note 
that the migration distances for the radioactive lipid peaks vary 
slightly on different chromatography plates. Peak identification is as 
follows: g, undegraded gal-cer substrate; c, ceramide; m, metabo-
lites except ceramide, including sphingomyelin and other biosynthe-
sized lipids. Control, untransformed normal control cells; Krabbe, 
untransformed cells from a Krabbe disease patient; Prosap-d, un-
transformed cells from the prosaposin-deficient fetus; Prosap-
d+crude sap C, the same cells with 16 ug crude sap C added per ml 
of medium; SapC-d, SV40-transformed cells from the original sap 
C-deficient patient (corresponds to the middle SapC-d sample in 
Fig. 2). 
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some experiments a specified amount (see Fig. 3) of crude sap C 
or pure saposin(s), dissolved in 0.1 ml water, was also added. After 
incubation for 3 days at 37°C, the cells were washed three times with 
phosphate-buffered saline and homogenized in 0.1 ml distilled water. 
One half of each homogenate was applied directly as a narrow streak 
to a thin layer silica gel plate (Merck, Darmstadt, Germany, no. 5626) 
and dried. The plate was first chromatographed twice with chloro-
form/methanol/acetic acid (47:1:2; by volume) to its upper edge, 
and then with chloroform/methanol/acetic acid/water (34:7:0.8:1; by 
volume) one third of the way up the plate. Radioscanning of the 
chromatograms revealed radioactive lipid peaks from the origin up-
wards in the following order: biosynthesized lipids including sphingo-
myelin (near the origin), the gal-cer substrate and free ceramide. The 
silica gel corresponding to each peak was scraped off the plate and the 
radioactivity determined by liquid scintillation counting. Lipid metab-
olites were identified according to our earlier experience with lipid 
loading tests [12,16]. 
3. Results 
When gal-cer, labelled with tritium in the ceramide moiety, 
was loaded on SV40-transformed or untransformed fibroblast 
cultures for 3 days a proportion (about 7-10%) of the lipid 
substrate was endocytosed and a portion of this was further 
metabolized. Gal-cer metabolites and undegraded gal-cer were 
analyzed radiochemically after thin layer chromatographic 
separation (Figs. 1-3) and the percentage of endocytosed ra-
dioactive gal-cer which was metabolized was taken as a meas-
ure of the gal-cer metabolic degradation rate. For cell lines 
where appreciable amounts of gal-cer were degraded, the in-
terassay variability in degradation rate was generally large, 
thus preventing the detection of possible small differences in 
degradation rate between different experimental conditions. 
For normal control cells a major part of the endocytosed 
substrate was degraded, with ceramide, the direct hydrolysis 
product of gal-cer, usually being the most significant radio-
active metabolite. Further metabolites, including radioactive 
biosynthesized lipids (in particular sphingomyelin), were also 
found, but their proportion only rarely exceeded that of cer-
amide. Despite their p-galactocerebrosidase deficiency, 
Krabbe cells metabolized appreciable amounts of the added 
gal-cer substrate, with a residual degradation rate about half 
that of control cells (Fig. 2; see also [27]). To check that the 
radioactive gal-cer substrate was indeed specific for P-galacto-
cerebrosidase, we also tested the substrate in in vitro assays 
using homogenates of the same Krabbe cells and found that 
the residual enzyme activity was less than 3% of the activity in 
control cells. By contrast to the other cell lines, when Prosap-
d cells were challenged with radioactive gal-cer, the cells pro-
duced very little labelled ceramide or other metabolites (Figs. 
1 and 2), indicating that gal-cer catabolism was severely im-
paired. 
Additional loading experiments were undertaken on Pro-
sap-d cells with different preparations of saposins (crude sap 
C, or pure saposins A, B, C or D) added to the culture me-
dium (Fig. 3). Sap B and sap D had little effect on the very 
low rate of gal-cer degradation in Prosap-d cells, stimulating 
the degradation by a factor of, at most, 1.5. On the other 
hand, addition of the indicated amounts of crude sap C, 
pure sap A or pure sap C stimulated gal-cer degradation in 
these cells 2-5-fold. However, complete correction of the gal-
cer breakdown defect (i.e. to the mean rate of degradation 
found in controls) was not attained in the Prosap-d cells. 
Also, at the concentration used, addition of a combination 
of sap A with sap C was no more effective than adding one 
or other of these two saposins on their own. 
Further gal-cer loading experiments were undertaken with 
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Fig. 2. Degradation of galactosyl [3H]ceramide (gal-cer) in intact fibroblast cultures from normal, sphingolipidosis, and saposin-deficient individ-
uals. The ordinate indicates the amount of radioactivity found in gal-cer metabolites, expressed as a percentage of the total radioactivity in cell 
bound lipids, after loading the cells with the radioactive lipid for 3 days. Lower column sections = ceramide; upper column sections = other me-
tabolites, including sphingomyelin and other biosynthesized lipids (see m in Fig. 1). The cell lines were as follows: controls, seven normal con-
trol cell lines; GMl, GMl gangliosidosis cells; FAR, Farber disease (ceramidosis) cells; Krabbe, two Krabbe disease cell lines; Prosap-d, pro-
saposin deficiency, with f and p indicating cells from the fetus and patient (each two experiments), respectively; SapC-d, saposin C-deficient cell 
line (three experiments). An asterisk denotes SV40-transformed cells. 
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Fig. 3. Degradation of galactosyl [3H]ceramide (gal-cer) in intact fibroblasts in the absence and presence of exogenous saposins. The ordinate 
indicates the amount of radioactivity found in gal-cer metabolites, expressed as a percentage of the total radioactivity in cell bound lipids, after 
loading the cells with the radioactive lipid for 3 days. Lower column sections = ceramide; upper column sections = other metabolites (see legend 
to Fig. 2). Columns marked n = 1 (controls), n = 4 (Prosap-d), and n = 3 (SapC-d) represent mean values for the indicated number of experi-
ments without added saposins, as shown in Fig. 2, for control, Prosap-d and SapC-d cells, respectively. An asterisk denotes SV40-transformed 
cells. For each cell type, the type of saposin added is indicated under the relevant column as follows: —, no added saposin; A, B, C and D, 
pure sap A, B, C and D, respectively; A+C, a mixture of sap A and sap C; and c, crude sap C. The saposin concentrations used (ug/ml me-
dium) are indicated and the cell types studied are as follows: controls, normal controls; Prosap-d, prosaposin deficiency, with f and p indicat-
ing the affected fetus and patient, respectively; SapC-d, saposin C deficiency. 
SV40-transformed SapC-d cells, to determine whether the en-
dogenous sap A present in these cells was able to sustain 
normal gal-cer catabolism in the absence of sap C. The 
growth behavior of the SapC-d cell line, as seen under the 
microscope, varied between experiments and may have con-
tributed to the observed biological variability in gal-cer deg-
radation rate. Nevertheless, the results indicated that gal-cer 
degradation was not significantly impaired in the SapC-d 
fibroblasts (the in vitro p-galactocerebrosidase activity for 
these cells was 59% of that in a transformed control cell 
line), with the variability in the rate of gal-cer degradation 
and in the conversion of ceramide to other metabolites being 
within the range found for control cell lines (Fig. 2). Results 
for the SapC-d cells in the presence of exogenous crude sap C 
or pure sap A were similar to those for unsupplemented 
SapC-d cells (Fig. 3). Gal-cer degradation was also normal 
in P-galactosidase-deficient (GM1 gangliosidosis) and ceram-
idase-deficient (Farber disease) fibroblasts (Fig. 2), however, 
the latter showed a higher proportion of radioactivity in cer-
amide. 
4. Discussion 
Previous investigations of human Prosap-d [14], and of the 
prosaposin knock-out model [15], have shown that a defi-
ciency of all four saposins (sap A, B, C and D) leads to 
storage of multiple glycosphingolipids, including different gal-
actolipids. Although the disturbed catabolism of lactosylcer-
amide and sulfogalactosylceramide has also been demon-
strated in Prosap-d cells in situ [13], the turnover of gal-cer 
had not been similarly studied in these cells. 
Since it had been predicted that sap C [5] or sap C and sap 
A [21] would activate gal-cer degradation in vivo, we expected 
that the Prosap-d fibroblasts would be deficient in gal-cer 
degradation, and this has now been confirmed. In addition, 
we were able to show that supplementation of the culture 
medium with sap A or sap C, at around 10 u,g protein per 
ml medium, activated the very low gal-cer degradation rate 2-
5-fold, up to a value between about 20-50% of the mean 
control rate, whereas gal-cer degradation in control and 
Krabbe cells was not affected by addition of these saposins 
(results not shown). Addition of higher concentrations of 
these two saposins to Prosap-d cells did not show consistently 
higher levels of activation, nor, at the concentration used, was 
a mixture of equal parts of sap A and sap C more effective 
than either saposin on its own. Sap B and sap D gave little 
stimulation of gal-cer degradation in Prosap-d cells, nor did 
they further increase metabolic processing of gal-cer in cells 
that were already stimulated with sap A and sap C (results not 
shown). Our results, therefore, provide strong support for the 
hypothesis that sap A and sap C are the activators which 
mediate gal-cer degradation in vivo. 
Possible reasons for the failure of added saposins to com-
pletely normalize gal-cer metabolism in the Prosap-d cells in-
clude the following. First, there may have been insufficient 
targeting of the activators to the lysosome to allow complete 
activation. An alternative explanation relates to the very low 
residual in vitro p-galactocerebrosidase activity in the Prosap-
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d cells [12,14,16]. The degradation rate for gal-cer was much 
lower in Prosap-d than in Krabbe cells with a similarly low 
enzyme activity, and the addition of sap A and sap C only 
corrected the rate in Prosap-d fibroblasts to a value similar to 
that in Krabbe cells (n.b., it has been shown [28] that even 
very low enzyme activities can be sufficient to allow consid-
erable sphingolipid breakdown). This raises the possibility 
that saposins may have an additional role in the biosynthesis, 
targeting or stabilization of the enzyme protein. A further 
possible explanation relates to the storage of a number of 
sphingolipids in Prosap-d [14], as it is conceivable that one 
or more of these lipids interferes with the interaction between 
exogenous saposins and P-galactocerebrosidase. Yet another 
explanation for the difference in degradation rates in the un-
supplemented Prosap-d and Krabbe cells, and for the failure 
to fully correct the defect in the sap A- and sap C-supple-
mented Prosap-d cells, is that the enzyme p-galactosidase 
may also contribute to gal-cer degradation [29], and the pu-
tative gal-cer degrading activity of this enzyme could also be 
compromised in Prosap-d. However, (3-galactosidase-deficient 
(GM1 gangliosidosis) cells showed normal metabolic process-
ing of gal-cer, and addition of sap B to sap A- and sap C-
stimulated Prosap-d cells did not increase the gal-cer degra-
dation rate. 
Physiological homology for sap A and sap C was predicted 
on the basis of their high sequence homology and their effects 
in vitro [21]. However, some functional heterology was later 
found when it was shown that these two saposins had distinct 
binding sites on P-glucocerebrosidase and that they could also 
act synergistically at certain saposin concentrations [6]. 
Although we did not observe synergy between sap A and 
sap C in their effect on gal-cer hydrolysis in fibroblasts under 
the conditions used, this does not exclude this possibility 
under different activator conditions or in different cell types. 
The fatal glucosylceramide storage associated with SapC-d 
[20,30,31] suggests that sap A cannot completely substitute for 
sap C in the in vivo situation. However, when we studied gal-
cer hydrolysis in SV40-transformed fibroblasts from the same 
patient no abnormality was found. Although the data indicate 
that sap A is involved in gal-cer hydrolysis in vivo, it remains 
open to what extent sap C is also involved. It is possible that 
both activators are required in tissues where there is a high 
substrate load (e.g. for gal-cer turnover in myelinotrophic 
cells, and in the macrophages for glucosylceramide degrada-
tion). 
In conclusion, the in situ gal-cer loading tests, using Prosap-
d and SapC-d fibroblasts, in the presence or absence of added 
saposins, has allowed further characterization of the role of 
saposins in gal-cer metabolism. If and when a patient with an 
isolated deficiency of sap A is identified, it should be possible 
to further clarify the functional relationship between sap A 
and sap C. 
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